◆ What the Market Isn't Pricing In

Coca-Cola presents the value investor with a subtler puzzle than a cheap stock: a wonderful business at a full-looking price, where the real question is whether the market has correctly weighed the one thing that could genuinely impair it. The stock trades around 27 times earnings with a dividend yield near 2.4%¹ — not cheap on the surface for a company growing revenue at mid-single digits, and a premium the market has long, and rightly, awarded Coca-Cola for the extraordinary durability and predictability of its cash flows. You are asked to pay a quality price for a quality business. The interesting question is what that price is implicitly assuming, and where it might be wrong in either direction.

The bear case, and the reason the multiple is not higher, is written in two structural fears. The first is the health and sugar backlash, now amplified by the GLP-1 weight-loss drugs that threaten to chemically suppress the very appetite Coca-Cola's whole business rests on — a genuinely novel risk to demand at its biological root, not merely at the margin of brand or price. The second is the slow-growth reality of a mature giant leaning ever harder on price to grow, in a world where volumes creep and currency headwinds recur. Together these cap the multiple: the market is unwilling to pay a true growth premium for a business it suspects is quietly, structurally, drinking a little less each year in its core.

What the market may be under-appreciating runs the other way. The GLP-1 fear, real as it is, is being applied to a company uniquely built to withstand it — one whose portfolio already spans water, zero-sugar, protein, and hydration, so that a consumer moderating their sugar intake can very often still be sold something Coca-Cola makes, and whose growth increasingly comes from a young, aspirational emerging-market middle class far from the reach of expensive Western weight-loss drugs. The recent results tell a story of a franchise still very much working: 2025 organic revenue up 5%², comparable earnings growing, guidance for 2026 raised to high-single-digit organic and near-double-digit comparable EPS growth, and pricing power on vivid display through the inflationary years. This is not a business in decline; it is a business compounding steadily while the market frets about a threat it has been adapting to for decades.

So the honest verdict is that Coca-Cola is priced as what it is — a wide-moat, slow-growing, supremely durable compounder facing a real but manageable structural headwind — and the debate is not about a mispricing so much as about conviction. If you believe the GLP-1 and sugar fears are overdone relative to a company this adaptive, that the emerging-market growth engine has decades to run, and that sixty-three years of rising dividends³ reflect a durability the market chronically underestimates in the abstract, then a wide-moat compounder at 24 times with a growing 3% yield is a fair price for a rare certainty — the kind of business you buy to hold for your grandchildren. If you believe the core is quietly dying and price can only paper over it for so long, the multiple is a trap. The moat is not in question. What is in question is whether the world will keep wanting what Coca-Cola sells — and on that, the company's century of adaptation, and its portfolio built for exactly this transition, are the evidence the pessimists tend to discount.